A Randomized Phase III Study Comparing Trastuzumab Plus Docetaxel (HT) Followed by 5-FU, Epirubicin, and Cyclophosphamide (FEC) to the Same Regimen Followed by Single-Agent Trastuzumab as Adjuvant Treatments for Early Breast Cancer
Phase of Trial: Phase III
Latest Information Update: 11 Mar 2015
At a glance
- Drugs Trastuzumab (Primary) ; Cyclophosphamide; Docetaxel; Epirubicin; Fluorouracil
- Indications Early breast cancer
- Focus Registrational; Therapeutic Use
- Acronyms SOLD
- 05 Mar 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 09 Dec 2014 United Kingdom Clinical Research Network record reports planned patient no as 2168.
- 05 Dec 2014 Accrual to date is 100% according to United Kingdom Clinical Research Network record.